| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Uridine-13C5 does not have a specific molecular target in the context of its use as an analytical standard. Unlabeled Uridine is a key pyrimidine nucleoside that is used in the synthesis of RNA and is involved in the regulation of various metabolic processes (e.g., glycogen synthesis).
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers that influence measurement during the drug development process. It's possible that the pharmacokinetics and functional range of medications contribute to the concern over mutagenesis [1].
In cell-free assays, Uridine-13C5 is used as a tracer to study the activity of enzymes involved in pyrimidine metabolism, such as uridine phosphorylase and UMP synthase. The conversion of the labeled uridine to its phosphorylated metabolites can be tracked by LC-MS to measure enzyme kinetics. |
| ln Vivo |
There is no in vivo activity for the labeled standard as a drug. When administered to animals, it is metabolized identically to unlabeled uridine. Researchers use it as a tracer to quantify glycogen synthesis in vivo by measuring the incorporation of the 13C5 label into glycogen in the liver or muscle using mass spectrometry.
|
| Enzyme Assay |
Uridine-13C5 is not used in standard enzyme/receptor binding protocols. As a tracer, it is added to an incubation mixture containing a biological matrix (e.g., liver homogenate) and cofactors. The production of labeled UMP, UDP, and UTP is then measured by LC-MS to determine the activity of the Uridine-Cytidine Kinase pathway.
|
| Cell Assay |
In a cellular study, cells are cultured in a medium supplemented with Uridine-13C5. The cells are harvested over a time course, and RNA is extracted and hydrolyzed. The incorporation of the 13C5 label into the RNA nucleotides is analyzed by LC-MS to measure the rate of RNA synthesis (transcription).
|
| Animal Protocol |
In an in vivo study to measure glycogen synthesis, animals are fasted and then administered a bolus of glucose along with Uridine-13C5. After a defined period (e.g., 1-4 hours), the liver is harvested, and glycogen is extracted and hydrolyzed. The enrichment of 13C5 in the uridine monophosphate (UMP) derived from UDP-glucose is measured by LC-MS.
|
| ADME/Pharmacokinetics |
As a stable isotope-labeled tracer, the PK properties of Uridine-13C5 are identical to unlabeled Uridine. It is rapidly taken up by the liver and other tissues. For injection purposes, it is formulated in a sterile saline solution to make a 2-10 mg/mL solution.
|
| Toxicity/Toxicokinetics |
Toxicity is not a significant concern for Uridine-13C5, as it is a naturally occurring nucleoside. At the doses used for metabolic tracing (mg/kg), it is considered safe and biocompatible. Standard safety precautions for handling biological buffers and reagents should be followed.
|
| References | |
| Additional Infomation |
Uridine-13C5 is a stable isotope-labeled tracer used in metabolic research. It is commonly used to investigate glycogen storage diseases (GSDs) and to study the "glucose paradox" by tracing the incorporation of uridine into hepatic glycogen. The 13C5 label ensures the tracer is easily distinguished from endogenous uridine by mass spectrometry.
|
| Molecular Formula |
C413C5H12N2O6
|
|---|---|
| Molecular Weight |
249.16
|
| Exact Mass |
249.086
|
| CAS # |
159496-16-9
|
| Related CAS # |
Uridine;58-96-8;Uridine-13C;201996-62-5;Uridine-13C,15N2;369656-75-7;Uridine-15N2;92487-68-8;Uridine-13C-1;478511-11-4;Uridine-13C-2;478511-14-7;Uridine-13C-3;478511-16-9;Uridine-d2;82740-98-5;Uridine-d;89434-96-8;Uridine 13C-4;35803-42-0;Uridine-d2-1;40632-21-1
|
| PubChem CID |
11747043
|
| Appearance |
Off-white to light brown solid powder
|
| LogP |
-2
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
371
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
[2H]C1=CN(C(=O)NC1=O)[13C@H]2[13C@@H]([13C@@H]([13C@H](O2)[13CH2]O)O)O
|
| InChi Key |
DRTQHJPVMGBUCF-WDBXUEINSA-N
|
| InChi Code |
InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)/t4-,6-,7-,8-/m1/s1/i1D,3+1,4+1,6+1,7+1,8+1
|
| Chemical Name |
5-deuterio-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxy(113C)methyl)(2,3,4,5-13C4)oxolan-2-yl]pyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0135 mL | 20.0674 mL | 40.1349 mL | |
| 5 mM | 0.8027 mL | 4.0135 mL | 8.0270 mL | |
| 10 mM | 0.4013 mL | 2.0067 mL | 4.0135 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
